Hepatopulmonary syndrome other imaging findings

Jump to navigation Jump to search

Hepatopulmonary syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatopulmonary syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatopulmonary syndrome other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatopulmonary syndrome other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatopulmonary syndrome other imaging findings

CDC on Hepatopulmonary syndrome other imaging findings

Hepatopulmonary syndrome other imaging findings in the news

Blogs on Hepatopulmonary syndrome other imaging findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Hepatopulmonary syndrome other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Angiography may be helpful in the diagnosis of hepatopulmonary syndrome. Non-invasive studies are preferred in diagnosis and management of patients with hepatopulmonary syndrome. Pulmonary angiography is indicated in known cases of HPS if sever hypoxia (partial pressure of oxygen is < 60 mmHg) is present, if the patient is a poor responsive to 100% oxygen, and if there is a strong suspicion of direct arterio-venous communications that would be amenable to embolization, based on chest CT scan findings. Rather than direct visualization of the pulmonary dilations (IPVSs), it can also demonstrate type of micro dilation in pulmonary vasculture.

Technetium 99m-labeled macroaggregated albumin scanning also may be helpful in the diagnosis of hepatopulmonary syndrome. labeled albumin macroaggregates (>20 microns in diameter) are injecting intravenously. Macroaggregates exceed the normal pulmonary capillary diameter and should be trapped normally. Scans that identify uptake of the radionucleotide by the brain suggest that the macroaggregates passed through either an intrapulmonary or intracardiac shunt. A calculated shunt fraction of above 6% is abnormal. Nevertheless, it can not distinguish between intracardiac and intrapulmonary shunting and has a lower sensitivity compared to contrast-enhanced echocardiography.

Other Imaging Findings

Pulmonary angiography

Non-invasive studies are preferred in diagnosis and management of patients with hepatopulmonary syndrome. Nevertheless in some cases such as likelihood of tromobotic accident, or when other noninvasive studies were not diagnostic, it is needed to evaluate the patient by means of angiography.

Indication for pulmonary angiography in known cases of HPS are as follows:

  • Sever hypoxia (partial pressure of oxygen is < 60 mmHg),
  • Poor response to 100% oxygen
  • Strong suspicion of direct arterio-venous communications that would be amenable to embolization, based on chest CT scan findings.

Rather than direct visualization of the pulmonary dilations (IPVSs), it can also demonstrate type of micro dilation in pulmonary vasculture as follows:

  • Type 1 (minimal):Finely diffuse, spidery infiltrates; may progress to type 1 (advanced).
  • Type 1 (advanced): Diffuse spongy or blotchy angiographic appearance
  • Type 2: Discrete, localized arterio-venous communications

Technetium 99m-labeled macroaggregated albumin scanning

  • labeled albumin macroaggregates (>20 microns in diameter) are injecting intravenously.[1]
  • Macroaggregates exceed the normal pulmonary capillary diameter and should be trapped normally.
  • In normal physiologic status, particles greater than 20 microns in diameter, (normal range of pulmonary capillary diameter is less than 8 to 15 microns) are trapped and filtered by the pulmonary capillary bed and do not appear in the left side of the heart and general circulation. However, in the presence of an intrapulmonary or intracardiac right-to-left shunt, those particles may be detected either in the left heart chambers or in the other organs such as brain or kidneys.
  • Scans that identify uptake of the radionucleotide by the brain suggest that the macroaggregates passed through either an intrapulmonary or intracardiac shunt.
  • Shunt fraction is defined as the percent of uptake in the brain compared to lungs.
  • 3% to 6% of albumin macroaggregates pass through the pulmonary vasculature in normal patients;Hence, a calculated shunt fraction of above<math>></math> 6% is abnormal.
  • The radionucleotide is also taken up by other organs, and the shunt fraction can be calculated in the kidneys as well.
  • Nevertheless the brain is preferred to the other organs and particularly kidneys because:
  • Free technetium deposits in the kidney but not in the brain and hence could falsely elevate the calculation.
  • Renal blood flow decreases significantly in cirrhotics and anemic patients with hyperdynamic circulation, on the other hand, the cerebrum perfusion maintains fairly constant in patients with anemia and most of cirrhotics (needs further investigation).
  • limitations
  • Can not distinguish between intracardiac and intrapulmonary shunting
  • lower sensitivity compared to contrast-enhanced echocardiography[2]

[3] [4]

[5] [6]

  • A schematic view of Technetium 99m-labeled macroaggregated albumin scanning . Particles bigger than 20 microns should not pass through the pulmonary vasculature and should be trapped in healthy subjects (1, 2, 3 ), but in patients with shunts such as patients with hepatopulmonary syndrome, they will appear in the left heart and the systemic circulation subsequently (4, 5, 6). Artwork by Soroush Seifirad, MD.


References

  1. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB (1998) Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 114 (2):305-10. PMID: 9453490
  2. Rodríguez-Roisin R, Krowka MJ (2008) Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med 358 (22):2378-87. DOI:10.1056/NEJMra0707185 PMID: 18509123
  3. Fallon MB, Abrams GA (2000) Pulmonary dysfunction in chronic liver disease. Hepatology 32 (4 Pt 1):859-65. DOI:10.1053/jhep.2000.7519 PMID: 11003635
  4. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C et al. (2004) Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10 (2):174-82. DOI:10.1002/lt.20016 PMID: 14762853
  5. Kennedy TC, Knudson RJ (1977) Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest 72 (3):305-9. DOI:10.1378/chest.72.3.305 PMID: 891282
  6. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA et al. (2016) International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 100 (7):1440-52. DOI:10.1097/TP.0000000000001229 PMID: 27326810